SCHEMBL2786217

SCHEMBL2786217

CC(C)(Sc1ccc(CCNCCCCCCCC(=O)Nc2ccc(F)cc2F)cc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.59
PPARA Q07869 4/20 0.59
PPARD Q03181 1/20 0.59
RAB9A P51151 2/20 0.49
POLB P06746 1/20 0.49
NPC1 O15118 1/20 0.41
HDAC3 O15379 5/20 0.41
HDAC1 Q13547 4/20 0.41
ULK1 O75385 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
MAPT P10636 1/20 0.39
FUCA1 P04066 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3683528 0.76 PPARG (0.64) PPARGPPARAPPARDRAB9APOLB
SCHEMBL20280514 0.75 PPARG (1.00) PPARGPPARAPPARD
Gsk-9578 SCHEMBL30475595 0.75 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL15480431 0.73 POLB (0.66) RAB9APOLBNPC1HDAC3HDAC1
SCHEMBL4133118 0.70 POLB (0.58) RAB9APOLBHDAC3HDAC1TP53
SCHEMBL31203495 0.70 HDAC3 (0.54) RAB9APOLBHDAC3HDAC1NCOR2
SCHEMBL10115113 0.69 HDAC3 (0.56) RAB9APOLBHDAC3HDAC1NCOR2
SCHEMBL12436841 0.69 PPARA (0.63) PPARGPPARAPPARDPOLBALDH1A1
SCHEMBL15480422 0.69 HDAC1 (0.63) RAB9APOLBNPC1HDAC3HDAC1
SCHEMBL6274364 0.68 POLB (0.58) RAB9APOLBNPC1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014015318-A1 SOLUBLE COMPOUNDS FOR IMPROVED GENE THERAPY METHODS BLUEBIRD BIO, INC. (US) 2014-01-23 WO claimed
US-20100240627-A1 COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS UNIVERSITEIT GENT 2010-09-23 US claimed
US-20090111782-A1 COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS GHENT UNIVERSITY (BE) 2009-04-30 US claimed
EP-4203941-A1 COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2023-07-05 EP disclosed
US-20230201226-A1 COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-06-29 US disclosed
WO-2022044014-A1 COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2022-03-03 WO disclosed
WO-2014015318-A1 SOLUBLE COMPOUNDS FOR IMPROVED GENE THERAPY METHODS BLUEBIRD BIO, INC. (US) 2014-01-23 WO disclosed
US-20110300129-A1 SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY UNIVERSITY OF ROCHESTER (US) 2011-12-08 US disclosed
US-20100240627-A1 COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS UNIVERSITEIT GENT 2010-09-23 US disclosed
WO-2010075037-A1 SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY UNIVERSITY OF ROCHESTER (US) 2010-07-01 WO disclosed
US-20090111782-A1 COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS GHENT UNIVERSITY (BE) 2009-04-30 US disclosed